[NR 565 ADVANCED PHARMACOLOGY 2026 - CHAMBERLAIN MIDTERM + FINAL]
– EXAM-STYLE QUESTIONS AND ANSWERS | VERIFIED AND WELL DETAILED
ANSWERS | PLUS RATIONALES | GUARANTEED PASS | 2026/27 LATEST UPDATE |
EXAM PREP | STUDY GUIDE | PRACTICE TEST
Section One: Questions 1 – 50
1. A 68-year-old patient with a history of chronic kidney disease (Stage 3b) is
being initiated on apixaban for stroke prevention in the setting of non-valvular
atrial fibrillation. Which of the following is the most critical component of the
initial assessment and ongoing monitoring plan for this patient?
A. Monitoring of serum creatinine and complete blood count only.
B. Baseline and periodic assessment of hepatic function tests.
C. Calculation of the patient's CHA₂DS₂-VASc and HAS-BLED scores.
D. Assessment of the patient's weight for appropriate dose adjustment.
Correct Answer: C. Calculation of the patient's CHA₂DS₂-VASc and HAS-BLED
scores.
*Rationale: * While monitoring renal function (A) is crucial for dosing apixaban, as
it is partially renally cleared, the initial step is to establish the patient's
thromboembolic and bleeding risk using validated scoring systems to confirm the
therapy's risk-benefit ratio and guide the duration of therapy. Hepatic function (B) is
less of a primary concern for apixaban's metabolism compared to other agents.
Weight-based dosing (D) is not a standard recommendation for apixaban; instead,
dosing is based on a combination of age, weight, and serum creatinine, but the
clinical decision to use the drug is predicated on risk stratification.
,2. A 45-year-old female patient is experiencing frequent, debilitating migraines.
She has a history of depression controlled with a selective serotonin reuptake
inhibitor (SSRI) and is inquiring about preventative treatment. Which of the
following classes of medications would be most prudent to avoid in this patient
due to the risk of a potentially life-threatening drug interaction?
A. Beta-blockers
B. Calcitonin gene-related peptide (CGRP) antagonists
C. Triptans
D. Topiramate
Correct Answer: C. Triptans
*Rationale: * Concomitant use of triptans and SSRIs, especially within a two-week
window, carries a risk of serotonin syndrome, a potentially fatal condition
characterized by autonomic instability, neuromuscular excitation, and cognitive
changes. While beta-blockers (A), CGRP antagonists (B), and topiramate (D) are all
prophylactic options for migraines, they do not carry the same acute, severe risk of
serotonin syndrome when combined with SSRIs.
3. A 72-year-old male patient with a diagnosis of heart failure with reduced
ejection fraction (HFrEF) is prescribed sacubitril/valsartan. The patient asks how
this medication will help his condition. What is the primary pharmacodynamic
effect that the advanced practice nurse should explain?
A. It inhibits angiotensin II and promotes vasodilation, leading to reduced cardiac
workload and remodeling.
,B. It directly stimulates the heart to contract with more force, improving ejection
fraction.
C. It blocks both the angiotensin II receptor and the breakdown of natriuretic
peptides, enhancing vasodilation and natriuresis.
D. It selectively inhibits the sympathetic nervous system, reducing heart rate and
myocardial oxygen demand.
Correct Answer: C. It blocks both the angiotensin II receptor and the
breakdown of natriuretic peptides, enhancing vasodilation and natriuresis.
*Rationale: * Sacubitril/valsartan is a neprilysin inhibitor combined with an
angiotensin II receptor blocker (ARB). The neprilysin inhibitor (sacubitril) prevents
the breakdown of endogenous natriuretic peptides, enhancing vasodilation and
sodium excretion, while the ARB (valsartan) blocks the harmful effects of
angiotensin II. This dual action (C) is the hallmark of its mechanism. It is not a
direct inotrope (B) and does not selectively block the sympathetic nervous system
(D), as beta-blockers do. While it leads to reduced cardiac workload, its primary
mechanism is more specific than just ACE/ARB inhibition (A).
4. A 55-year-old patient with type 2 diabetes mellitus and established
atherosclerotic cardiovascular disease (ASCVD) is being started on a GLP-1
receptor agonist. Which of the following medications in this class has the
strongest evidence for reducing major adverse cardiovascular events (MACE) in
this specific patient population?
A. Dulaglutide
B. Exenatide
, C. Liraglutide
D. Semaglutide
Correct Answer: D. Semaglutide
*Rationale: * The SUSTAIN-6 trial demonstrated that semaglutide significantly
reduced the risk of MACE (including cardiovascular death, nonfatal myocardial
infarction, and nonfatal stroke) in patients with type 2 diabetes and high
cardiovascular risk. While liraglutide (C) also showed cardiovascular benefit in the
LEADER trial, the evidence for semaglutide is considered robust and often cited as a
preferred agent for its cardiovascular protective effects. Dulaglutide (A) and
exenatide (B) are also options but do not have the same level of evidence for
ASCVD risk reduction as semaglutide.
5. A patient is initiated on rivaroxaban for the treatment of deep vein
thrombosis and pulmonary embolism. The patient's current medications
include amiodarone, diltiazem, and atorvastatin. Which of the following
describes the most significant pharmacokinetic concern with this medication
regimen?
A. Amiodarone and diltiazem may increase rivaroxaban levels via P-glycoprotein
inhibition.
B. Atorvastatin and rivaroxaban both inhibit platelet aggregation, leading to
increased bleeding risk.
C. Diltiazem will decrease the renal clearance of rivaroxaban, requiring dose
adjustment.
D. Amiodarone and rivaroxaban both prolong the QT interval, increasing the risk
of torsades de pointes.
– EXAM-STYLE QUESTIONS AND ANSWERS | VERIFIED AND WELL DETAILED
ANSWERS | PLUS RATIONALES | GUARANTEED PASS | 2026/27 LATEST UPDATE |
EXAM PREP | STUDY GUIDE | PRACTICE TEST
Section One: Questions 1 – 50
1. A 68-year-old patient with a history of chronic kidney disease (Stage 3b) is
being initiated on apixaban for stroke prevention in the setting of non-valvular
atrial fibrillation. Which of the following is the most critical component of the
initial assessment and ongoing monitoring plan for this patient?
A. Monitoring of serum creatinine and complete blood count only.
B. Baseline and periodic assessment of hepatic function tests.
C. Calculation of the patient's CHA₂DS₂-VASc and HAS-BLED scores.
D. Assessment of the patient's weight for appropriate dose adjustment.
Correct Answer: C. Calculation of the patient's CHA₂DS₂-VASc and HAS-BLED
scores.
*Rationale: * While monitoring renal function (A) is crucial for dosing apixaban, as
it is partially renally cleared, the initial step is to establish the patient's
thromboembolic and bleeding risk using validated scoring systems to confirm the
therapy's risk-benefit ratio and guide the duration of therapy. Hepatic function (B) is
less of a primary concern for apixaban's metabolism compared to other agents.
Weight-based dosing (D) is not a standard recommendation for apixaban; instead,
dosing is based on a combination of age, weight, and serum creatinine, but the
clinical decision to use the drug is predicated on risk stratification.
,2. A 45-year-old female patient is experiencing frequent, debilitating migraines.
She has a history of depression controlled with a selective serotonin reuptake
inhibitor (SSRI) and is inquiring about preventative treatment. Which of the
following classes of medications would be most prudent to avoid in this patient
due to the risk of a potentially life-threatening drug interaction?
A. Beta-blockers
B. Calcitonin gene-related peptide (CGRP) antagonists
C. Triptans
D. Topiramate
Correct Answer: C. Triptans
*Rationale: * Concomitant use of triptans and SSRIs, especially within a two-week
window, carries a risk of serotonin syndrome, a potentially fatal condition
characterized by autonomic instability, neuromuscular excitation, and cognitive
changes. While beta-blockers (A), CGRP antagonists (B), and topiramate (D) are all
prophylactic options for migraines, they do not carry the same acute, severe risk of
serotonin syndrome when combined with SSRIs.
3. A 72-year-old male patient with a diagnosis of heart failure with reduced
ejection fraction (HFrEF) is prescribed sacubitril/valsartan. The patient asks how
this medication will help his condition. What is the primary pharmacodynamic
effect that the advanced practice nurse should explain?
A. It inhibits angiotensin II and promotes vasodilation, leading to reduced cardiac
workload and remodeling.
,B. It directly stimulates the heart to contract with more force, improving ejection
fraction.
C. It blocks both the angiotensin II receptor and the breakdown of natriuretic
peptides, enhancing vasodilation and natriuresis.
D. It selectively inhibits the sympathetic nervous system, reducing heart rate and
myocardial oxygen demand.
Correct Answer: C. It blocks both the angiotensin II receptor and the
breakdown of natriuretic peptides, enhancing vasodilation and natriuresis.
*Rationale: * Sacubitril/valsartan is a neprilysin inhibitor combined with an
angiotensin II receptor blocker (ARB). The neprilysin inhibitor (sacubitril) prevents
the breakdown of endogenous natriuretic peptides, enhancing vasodilation and
sodium excretion, while the ARB (valsartan) blocks the harmful effects of
angiotensin II. This dual action (C) is the hallmark of its mechanism. It is not a
direct inotrope (B) and does not selectively block the sympathetic nervous system
(D), as beta-blockers do. While it leads to reduced cardiac workload, its primary
mechanism is more specific than just ACE/ARB inhibition (A).
4. A 55-year-old patient with type 2 diabetes mellitus and established
atherosclerotic cardiovascular disease (ASCVD) is being started on a GLP-1
receptor agonist. Which of the following medications in this class has the
strongest evidence for reducing major adverse cardiovascular events (MACE) in
this specific patient population?
A. Dulaglutide
B. Exenatide
, C. Liraglutide
D. Semaglutide
Correct Answer: D. Semaglutide
*Rationale: * The SUSTAIN-6 trial demonstrated that semaglutide significantly
reduced the risk of MACE (including cardiovascular death, nonfatal myocardial
infarction, and nonfatal stroke) in patients with type 2 diabetes and high
cardiovascular risk. While liraglutide (C) also showed cardiovascular benefit in the
LEADER trial, the evidence for semaglutide is considered robust and often cited as a
preferred agent for its cardiovascular protective effects. Dulaglutide (A) and
exenatide (B) are also options but do not have the same level of evidence for
ASCVD risk reduction as semaglutide.
5. A patient is initiated on rivaroxaban for the treatment of deep vein
thrombosis and pulmonary embolism. The patient's current medications
include amiodarone, diltiazem, and atorvastatin. Which of the following
describes the most significant pharmacokinetic concern with this medication
regimen?
A. Amiodarone and diltiazem may increase rivaroxaban levels via P-glycoprotein
inhibition.
B. Atorvastatin and rivaroxaban both inhibit platelet aggregation, leading to
increased bleeding risk.
C. Diltiazem will decrease the renal clearance of rivaroxaban, requiring dose
adjustment.
D. Amiodarone and rivaroxaban both prolong the QT interval, increasing the risk
of torsades de pointes.
